Table 6.  Neurological and urogenital adverse reactions observed per number of patients.
Adverse reaction  Studies  Total patients, n  Patients with adverse reactions, n (%)  (min%–max%) †
Neurological
   Headache  [ 2, 18, 29, 33, 38, 41, 55, 59, 70, 71, 81, 84, 85, 98, 101, 104, 116]  2516  150 (6)  (1–50) [ 101] - [ 70]
  Intravenous administration  [ 18, 33, 41, 59, 70, 71, 81, 85, 98, 101, 104]  1271  42 (3)  (1–50) [ 101] - [ 70]
  Transdermal application  [ 2, 29, 55]  1197  102 (8)  (5–35) [ 55] - [ 2]
  Intravesical administration  [ 38]  20  1 (5)
  Rectal administration  [ 116]  21  3 (14)
  >1 administration route  [ 84]  7  2 (29)
   Seizures  [ 18, 36, 47]  301  2 (1)  (0–2) [ 18] - [ 47]
   Neurological symptoms,  unspecified  [ 86]  144  5 (3)
   Transient CN III and IV palsy  [ 34]  12  1 (8)
   Severe encephalopathy  [ 99]  124  1 (1)
Urogenital
   Pelvic discomfort/pain/  irritation  [ 38, 49, 97]  107  10 (9)  (6–30) [ 49] - [ 38]
   Dysuria/strangury  [ 49]  36  6 (17)
   Renal and urinary disorder  [ 49]  36  8 (22)
†Incidences of the adverse reactions have been calculated for all the individual studies. (min%–max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.